PMV Pharmaceuticals, Inc. (PMVP) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US69353Y1038
PMV Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -86.21 m USD |
| EBIT | -79.91 m USD |
| Net income | -77.74 m USD |
| Diluted EPS – continuing operations | -1.48 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
More stocks
- Alan Allman Associates SA (AAA.PA)
- eWork Group AB (EWRK.ST)
- DeFi Development Corp. (DFDV)
- Western Asset Investment Grade Defined Opportunity Closed Fund (IGI)
- Telechips Inc (054450.KQ)
- BRC Inc. (BRCC)
- Polynet PCL (POLY.BK)
- Spyrosoft S.A. (SPR.WA)
- Honor Seiki Co., Ltd. (7709.TWO)
- M3 Technology Inc. (6799.TW)
- Golden Destinations Group Berhad (0398.KL)
- HASEN-IMMOBILIEN N (ABHA.MU)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.